DDPH, a novel antihypertensive agent, is a potential dual inhibitor of hepatic CYP2D and CYP3A
详细信息 查看全文
- 作者：Yinsong Zhu1 ; zhuysong@163.com" class="auth_mail" title="E-mail the corresponding author ; Jiong Hu1 ; hu@vrc.uni-frankfurt.de" class="auth_mail" title="E-mail the corresponding author ; Wenjuan He hwj073683@163.com" class="auth_mail" title="E-mail the corresponding author ; Xiujuan Gao xj_gao@hust.edu.cn" class="auth_mail" title="E-mail the corresponding author ; Ping Ren 8renping@163.com" class="auth_mail" title="E-mail the corresponding author ; Hui Chen ; Chenhuitjmu@163.com" class="auth_mail" title="E-mail the corresponding author
- 关键词：DDPH ; Cytochrome P450 ; Propafenone ; Drug&ndash ; drug interaction ; Enzyme kinetics
- 刊名：Chemico-Biological Interactions
- 出版年：2016
- 出版时间：5 March 2016
- 年：2016
- 卷：247
- 期：Complete
- 页码：55-63
- 全文大小：1402 K
文摘
- •
DDPH inhibits CYP2D1 and CYP3A1 activity, mRNA and protein expression in rats.
- •
DDPH is a potential dual inhibitor of hepatic CYP2D and CYP3A in rats and humans.
- •
DDPH affects the pharmacokinetics of propafenone, leading to an increase of AUC.
- •
Caution is required when DDPH is co-administered with CYP2D or CYP3A substrates.